30,464 Shares in BeiGene, Ltd. (NASDAQ:BGNE) Purchased by XY Capital Ltd

XY Capital Ltd acquired a new stake in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 30,464 shares of the company's stock, valued at approximately $6,839,000. BeiGene accounts for 2.3% of XY Capital Ltd's investment portfolio, making the stock its 6th largest position.

Other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. grew its position in BeiGene by 156.3% in the third quarter. Blue Trust Inc. now owns 123 shares of the company's stock valued at $28,000 after acquiring an additional 75 shares in the last quarter. Raymond James & Associates increased its position in shares of BeiGene by 0.4% during the second quarter. Raymond James & Associates now owns 21,275 shares of the company's stock worth $3,035,000 after acquiring an additional 76 shares during the last quarter. Truist Financial Corp boosted its holdings in BeiGene by 10.1% in the second quarter. Truist Financial Corp now owns 1,521 shares of the company's stock valued at $217,000 after purchasing an additional 140 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in BeiGene during the 3rd quarter valued at approximately $36,000. Finally, ProShare Advisors LLC increased its holdings in BeiGene by 8.1% during the 1st quarter. ProShare Advisors LLC now owns 2,902 shares of the company's stock worth $454,000 after purchasing an additional 217 shares during the last quarter. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeiGene Stock Performance

BGNE stock traded down $1.35 during mid-day trading on Friday, reaching $205.47. The company had a trading volume of 207,402 shares, compared to its average volume of 323,515. The stock's 50-day simple moving average is $212.41 and its two-hundred day simple moving average is $180.69. The stock has a market capitalization of $20.00 billion, a P/E ratio of -40.45 and a beta of 0.63. The company has a quick ratio of 1.75, a current ratio of 1.98 and a debt-to-equity ratio of 0.06. BeiGene, Ltd. has a one year low of $126.97 and a one year high of $248.16.

BeiGene (NASDAQ:BGNE - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, beating the consensus estimate of ($2.27) by $1.12. The firm had revenue of $929.20 million for the quarter, compared to the consensus estimate of $810.34 million. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The firm's revenue for the quarter was up 56.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($3.64) EPS. Research analysts anticipate that BeiGene, Ltd. will post -5 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on BGNE. JPMorgan Chase & Co. lifted their price target on shares of BeiGene from $200.00 to $235.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 22nd. JMP Securities assumed coverage on shares of BeiGene in a research report on Wednesday, September 18th. They set a "market outperform" rating and a $288.00 price target on the stock. Finally, Citigroup boosted their price objective on BeiGene from $269.00 to $288.00 and gave the company a "buy" rating in a report on Thursday, August 8th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $246.21.

Insider Transactions at BeiGene

In other BeiGene news, CEO John Oyler sold 6,175 shares of the company's stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total value of $1,433,958.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, SVP Chan Henry Lee sold 1,202 shares of the stock in a transaction on Monday, September 30th. The stock was sold at an average price of $237.10, for a total transaction of $284,994.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John Oyler sold 6,175 shares of the stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total value of $1,433,958.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,070 shares of company stock valued at $4,901,050. Corporate insiders own 7.43% of the company's stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.